Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_assertion description "[The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_assertion evidence source_evidence_literature NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_assertion SIO_000772 22525818 NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_assertion wasDerivedFrom befree-20150227 NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_assertion wasGeneratedBy ECO_0000203 NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.
- befree-20150227 importedOn "2015-02-27" NP230402.RAiaTjO_UgPiWuol9-wh-lfO0Y26SjkZabEO3Ip_E3ZkE130_provenance.